DHP-Frimal

DHP-Frimal

Manufacturer:

Mersifarma TM
Concise Prescribing Info
Contents
Dihydroartemisinin 40 mg, piperaquine phosphate 320 mg
Indications/Uses
Uncomplicated malaria disease caused by P. falciparum &/or P. vivax malaria.
Dosage/Direction for Use
Day 1-3: ≥15 yr, ≥60 kg 4 tab ≥15 yr, 41-59 kg 3 tab 10-14 yr, 31-40 kg 2 tab 5-9 yr, 18-30 kg 1.5 tab 1-4 yr, 11-17 kg 1 tab 2-11 mth, 6-10 kg 0.5 tab 0-1 mth, <5 kg 0.25 tab
Administration
Should be taken with food.
Contraindications
Hypersensitivity to dihydroartemisinin & piperaquine phosphate. Severe renal damage, liver disease & blood disorders. Severe malaria; patients taking drugs that prolong QTc interval; symptomatic cardiac arrhythmias, severe HTN, left ventricular hypertrophy eg, hypertrophic cardiomyopathy; congestive cardiac failure accompanied by reduced left ventricle ejection fraction; electrolyte disturbance eg, hypokalemia, hypocalcemia or hypomagnesaemia. Pregnancy.
Special Precautions
Hepatic & kidney function obstacle.
Adverse Reactions
Nausea, vomiting, stomachache, diarrhea & loss of appetite. Dizziness, headache, insomnia; allergic reaction eg, rash, pruritus. Transient decrease of peripheral erythrocyte, trancient increased of SGPT, SGOT & blood creatinine. Laboratory exam abnormalities.
Drug Interactions
MIMS Class
ATC Classification
P01BF05 - artenimol and piperaquine ; Belongs to the class of artemisinin and derivatives, combinations. Used in the management of malaria.
Presentation/Packing
Form
DHP-Frimal FC tab
Packing/Price
1 × 9's (Rp40,000/boks)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in